Human Urinary Kallidinogenase decreases recurrence risk and promotes good recovery

Author:

Han Dong1,Chen Xin2,Li Dongmei3,Liu Shuang1,Lyu Yi3,Feng Juan1ORCID

Affiliation:

1. Department of Neurology; The Affiliated Shengjing Hospital of China Medical University; Shenyang Liaoning China

2. Department of Neurology; Shanghai Fifth People's Hospital; Fudan University; Shanghai China

3. Department of Medical Affairs; Techpool Bio-pharma Co., Ltd; Guangzhou Guangdong China

Publisher

Wiley

Subject

Behavioral Neuroscience

Reference22 articles.

1. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack;Adams;Stroke,2008

2. One-year incidence, time trends, and predictors of recurrent ischemic stroke in Sweden from 1998 to 2010;Bergström;Stroke,2017

3. Experimental therapy with tissue kallikrein against cerebral ischemia;Chao;Frontiers in Bioscience,2006

4. Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB;Chen;Journal of Cerebral Blood Flow and Metabolism,2010

5. A multicenter, randomized, double-blinded and placebo-controlled study of acute brain infarction treated by human urinary kallidinogenase;Ding;Zhonghua Shen Jing Ge Za Zhi,2007

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3